<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: financial condition", fill: "#cd5700"},
{source: "1: financial condition", target: "1: future vary significantly depending on", fill: "#cd5700"},
{source: "1: financial condition", target: "5: operations", fill: "#0093af"},
{source: "5: operations", target: "5: future vary significantly from", fill: "#0093af"},
{source: "5: operations", target: "9: development", fill: "#ad6f69"},
{source: "9: development", target: "9: approval within", fill: "#ad6f69"},
{source: "9: approval within", target: "9: expenditure", fill: "#ad6f69"},
{source: "9: development", target: "12: tissue augmentation market", fill: "#1560bd"},
{source: "12: tissue augmentation market", target: "12: adhesions", fill: "#1560bd"},
{source: "12: adhesions", target: "12: regulatory approval", fill: "#1560bd"},
{source: "12: regulatory approval", target: "12: commercial marketing", fill: "#1560bd"},
{source: "12: tissue augmentation market", target: "21: regulations", fill: "#0abab5"},
{source: "21: regulations", target: "21: effectiveness", fill: "#0abab5"},
{source: "21: effectiveness", target: "21: new indications", fill: "#0abab5"},
{source: "21: new indications", target: "21: different facility", fill: "#0abab5"},
{source: "21: different facility", target: "21: manufacture process", fill: "#0abab5"},
{source: "21: manufacture process", target: "21: design specifications", fill: "#0abab5"},
{source: "21: regulations", target: "59: Under ", fill: "#008000"},
{source: "59: Under ", target: "59: of the BL Agreement ", fill: "#008000"},
{source: "59: of the BL Agreement ", target: "59: effective", fill: "#008000"},
{source: "59: effective", target: "59: December ", fill: "#008000"},
{source: "59: December ", target: "59: exclusive global supplier", fill: "#008000"},
{source: "59: exclusive global supplier", target: "59: ophthalmic viscoelastic", fill: "#008000"},
{source: "59: Under ", target: "START_HERE", fill: "#008000"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Life and Health Insurance</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_12">December 12</a></td>
      <td>December 12 is the 346th day of the year (347th in leap years) in the Gregorian calendar;  19 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n627 – Battle of Nineveh: A Byzantine army under Emperor Heraclius defeats Emperor Khosrau II's Persian forces, commanded by General Rhahzadh.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ANIKA THERAPEUTICS INC      ITEM 1A        RISK FACTORS       Our operating results and <font color="blue">financial condition</font> have varied in the past and     could in the <font color="blue">future vary <font color="blue">significant</font>ly depending on</font> a number of factors</td>
    </tr>
    <tr>
      <td>From time to time, information <font color="blue">provided by us</font> or statements made by our     employees contain “forward-looking” information that <font color="blue">involves risks</font> and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>In particular, statements contained in this Form 10-K, and in     the <font color="blue"><font color="blue">documents</font> <font color="blue">incorporated by reference into</font></font> this Form 10-K, that are not     <font color="blue">historical facts</font>, including, but not limited to <font color="blue">statements concerning new</font>     products, product <font color="blue">development</font> and offerings, product and <font color="blue">price <font color="blue">competition</font></font>,     <font color="blue">competition</font>  and strategy, customer diversification, product price and     inventory, contingent consideration payments, deferred revenues, economic     and market <font color="blue">conditions</font>, potential government regulation, seasonal factors,     <font color="blue">international</font> expansion, revenue <font color="blue">recognition</font>, profits, growth of revenues,     <font color="blue">composition</font>  of revenues, cost of revenues, operating expenses, sales,     marketing and support expenses, general and <font color="blue">administrative</font> expenses, product     gross profit, interest income, anticipated operating and <font color="blue">capital <font color="blue">expenditure</font></font>     <font color="blue">requirements</font>, cash inflows, contractual <font color="blue">obligation</font>s, tax rates, SFAS 123R,     leasing and subleasing <font color="blue">activities</font>, <font color="blue">acquisition</font>s, liquidity, <font color="blue">litigation</font>     matters, intellectual property matters, <font color="blue">distribution</font> channels, stock price,     <font color="blue">third party licenses</font> and <font color="blue">potential debt</font> or <font color="blue">equity <font color="blue">financings</font> constitute</font>     forward-looking statements and are made under the <font color="blue">safe harbor provisions</font> of     Section 27 of the <font color="blue">Securities Act </font>of 1933 as amended, <font color="blue">and Section </font>21E of the     <font color="blue">Securities Exchange Act </font>of 1934, as amended</td>
    </tr>
    <tr>
      <td>These statements are neither     <font color="blue">promises nor guarantees</font></td>
    </tr>
    <tr>
      <td>Our actual results of <font color="blue">operations</font> and financial     condition have varied and could in the <font color="blue">future vary <font color="blue">significant</font>ly from</font> those     stated in any forward-looking statements</td>
    </tr>
    <tr>
      <td>The following factors, among     others, could cause actual results to <font color="blue">differ <font color="blue">materially</font> from</font> those contained     in forward-looking statements made in this Form 10-K, in the <font color="blue">documents</font>     <font color="blue">incorporated by reference into</font> this Form 10-K or <font color="blue">presented elsewhere by</font> our     <font color="blue"><font color="blue">management</font> from</font> time to time</td>
    </tr>
    <tr>
      <td>Such factors, <font color="blue">among others</font>, could have a     material  adverse  effect upon our business, results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our business is subject to <font color="blue">comprehensive</font> and <font color="blue">varied government regulation</font>     and, as a result, failure to obtain FDA or other <font color="blue">governmental approvals</font> for     our  <font color="blue"><font color="blue">products may</font> <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font></font> our business, results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">development</font> and <font color="blue">approval within</font> the FDA framework takes a number of     years and involves the <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>There can be no     assurance that the FDA will grant approval for our <font color="blue"><font color="blue">new products</font> on</font> a timely     basis  if at all, or that FDA <font color="blue">review will</font> not <font color="blue">involve delays</font> that will     <font color="blue"><font color="blue">adversely</font> affect</font> our ability to <font color="blue"><font color="blue">commercialize</font> <font color="blue">additional</font> products</font> or expand     <font color="blue">permitted uses</font> of <font color="blue">existing products</font>, or that the <font color="blue"><font color="blue">regulatory</font> framework will</font>     not change, or that <font color="blue"><font color="blue">additional</font> regulation will</font> not arise at any stage of our     product <font color="blue">development</font> process which may <font color="blue"><font color="blue">adversely</font> affect</font> approval of or delay     an <font color="blue">application</font> or require <font color="blue">additional</font> <font color="blue">expenditure</font>s by us</td>
    </tr>
    <tr>
      <td>In the event our     <font color="blue">future products</font> are regulated as human drugs or biologics, the FDA’s review     process of <font color="blue"><font color="blue">such products</font> typically would</font> be <font color="blue"><font color="blue">substantially</font> longer</font> and more     <font color="blue">expensive than</font> the <font color="blue">review process</font> to which they are currently subject as     devices</td>
    </tr>
    <tr>
      <td>Our HA products under <font color="blue">development</font>, including a product for the cosmetic     <font color="blue">tissue augmentation market</font> (CTA), and INCERT®, a product designed to prevent     surgical  <font color="blue">adhesions</font>,  have  not  obtained US <font color="blue"><font color="blue">regulatory</font> approval</font> for     <font color="blue">commercial marketing</font> and sale</td>
    </tr>
    <tr>
      <td>We received <font color="blue">Conformite Europeenne </font>marking (CE     marking), a foreign <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">commercial marketing</font> and sale,     for INCERT in the <font color="blue">third quarter</font> of 2004</td>
    </tr>
    <tr>
      <td>In addition, we filed a pre-market     approval <font color="blue">application</font> in <font color="blue">September </font>2005 for our CTA product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     you that:       ·       we will begin or <font color="blue">successfully</font> complete US <font color="blue"><font color="blue">clinical trial</font>s</font> for     these products;       ·       the <font color="blue">clinical data will support</font> the efficacy of these products;       ·        we  will  be able to <font color="blue">successfully</font> complete the FDA or foreign     <font color="blue"><font color="blue">regulatory</font> approval</font> process, where required; or       11     ______________________________________________________________________       ·       <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> will support a PMA <font color="blue">application</font> and/or FDA     approval or other foreign <font color="blue"><font color="blue">regulatory</font> approval</font>s, where required, in a timely     manner or at all</td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot assure</font> you that any delay in receiving FDA <font color="blue">approvals will</font> not     <font color="blue">adversely</font>  affect our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>Furthermore, even if we do     receive FDA approval:       ·       the <font color="blue">approval may</font> include <font color="blue"><font color="blue">significant</font> <font color="blue"><font color="blue">limitations</font> on</font></font> the <font color="blue">indications</font>     and other claims sought for use for which the <font color="blue">products may</font> be marketed;       ·       the <font color="blue">approval may</font> include other <font color="blue"><font color="blue">significant</font> <font color="blue">conditions</font></font> of approval     such as post-market testing, tracking, or <font color="blue">surveillance <font color="blue">requirements</font></font>; and       ·       <font color="blue"><font color="blue">meaningful sales</font> may never</font> be achieved</td>
    </tr>
    <tr>
      <td>Once obtained, <font color="blue">marketing approval</font> can be <font color="blue">withdrawn by</font> the FDA for a number     of reasons, including, <font color="blue">among others</font>, the failure to <font color="blue">comply with</font> <font color="blue">regulatory</font>     standards,  or the occurrence of <font color="blue">unforeseen problems following initial</font>     approval</td>
    </tr>
    <tr>
      <td>We may be required to make <font color="blue">further filings with</font> the FDA under     <font color="blue">certain <font color="blue">circumstances</font></font></td>
    </tr>
    <tr>
      <td>The FDA’s <font color="blue">regulations</font> require a PMA supplement for     certain changes if they affect the safety and <font color="blue"><font color="blue">effective</font>ness</font> of an approved     device, including, but not limited to, new <font color="blue">indications</font> for use, labeling     changes, the use of a <font color="blue">different facility</font> to <font color="blue">manufacture</font>, process or package     the device, and changes in performance or <font color="blue">design specifications</font></td>
    </tr>
    <tr>
      <td>Changes in     <font color="blue">manufacturing</font> procedures or methods of <font color="blue">manufacturing</font> that may affect safety     and <font color="blue"><font color="blue">effective</font>ness</font> may be deemed approved after a 30-day notice unless the     FDA requests a 135-day supplement</td>
    </tr>
    <tr>
      <td>Our failure to receive approval of a PMA     supplement regarding the use of a different <font color="blue">manufacturing</font> facility or any     other change <font color="blue">affecting</font> the safety or <font color="blue"><font color="blue">effective</font>ness</font> of an approved device on     a  timely  basis, or at all, may have a material adverse effect on our     business, <font color="blue">financial condition</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">could also</font>     limit or prevent the <font color="blue">manufacture</font> or <font color="blue">distribution</font> of our products and has the     power to require the recall of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>delay or cost in     obtaining, or failure to obtain FDA approval to <font color="blue">market products</font>, any FDA     <font color="blue"><font color="blue">limitations</font> on</font> the use of our products, or any withdrawal or suspension of     approval or <font color="blue">rescission</font> of <font color="blue">approval by</font> the FDA could have a material adverse     effect on our business, <font color="blue">financial condition</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, all FDA approved or cleared products <font color="blue">manufacture</font>d by us must be     <font color="blue">manufacture</font>d in <font color="blue">compliance with</font> the FDA’s Good Manufacturing Practices (GMP)     <font color="blue">regulations</font> and, for <font color="blue">medical devices</font>, the FDA’s Quality System Regulations     (QSR)</td>
    </tr>
    <tr>
      <td><font color="blue">Ongoing  </font>compliance  with  QSR and other applicable <font color="blue">regulatory</font>     <font color="blue">requirements</font> is <font color="blue">enforced through periodic inspection by</font> state and federal     agencies, including the <font color="blue">FDA The FDA </font>may inspect us and our <font color="blue">facilities from</font>     time to time to determine whether we are in <font color="blue">compliance with</font> <font color="blue">regulations</font>     relating  to  medical  device  and  <font color="blue">manufacturing</font> companies, including     <font color="blue">regulations</font> concerning <font color="blue">manufacturing</font>, testing, quality control and product     <font color="blue">labeling practices</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to <font color="blue">comply with</font>     current  or  future  FDA <font color="blue">requirements</font> applicable to the <font color="blue">manufacture</font> of     products</td>
    </tr>
    <tr>
      <td>FDA <font color="blue">regulations</font> depend heavily on <font color="blue">administrative</font> interpretation and we     <font color="blue">cannot assure</font> you that the <font color="blue">future interpretations</font> made by the FDA or other     <font color="blue">regulatory</font> bodies, with possible retroactive effect, will not <font color="blue">adversely</font>     <font color="blue">affect us</font></td>
    </tr>
    <tr>
      <td>In addition, changes in the existing <font color="blue">regulations</font> or adoption of     new governmental <font color="blue">regulations</font> or <font color="blue">policies could prevent</font> or delay <font color="blue">regulatory</font>     approval of our products</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> could result in,     among other things, warning letters, fines, <font color="blue">injunctions</font>, civil penalties,     recall or seizure of products, total or partial suspension of production,     refusal <font color="blue">of the FDA </font>to grant pre-market clearance or pre-market approval for     devices, withdrawal of approvals and criminal <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">regulations</font> enforced by the FDA, we are subject to other     existing  and  future  federal,  state, local and foreign <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">regulatory</font> bodies often establish <font color="blue">regulations</font> governing       12     ______________________________________________________________________       product standards, packing <font color="blue">requirements</font>, labeling <font color="blue">requirements</font>, import     restrictions, tariff <font color="blue">regulations</font>, duties and tax <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We cannot     assure  you that we will be able to achieve and/or maintain compliance     required for CE marking or other foreign <font color="blue"><font color="blue">regulatory</font> approval</font>s for any or all     of our products or that we will be able to produce our products in a timely     and profitable manner while complying with applicable <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Federal,     state, local and foreign <font color="blue">regulations</font> regarding the <font color="blue">manufacture</font> and sale of     <font color="blue">medical products</font> are subject to change</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> what impact, if     any, such changes might have on our business</td>
    </tr>
    <tr>
      <td>The  process  of obtaining <font color="blue">approvals from</font> the FDA and other <font color="blue">regulatory</font>     <font color="blue">authorities</font> can be costly, time consuming, and subject to <font color="blue">unanticipated</font>     delays</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that approvals or <font color="blue">clearances</font> of our products     will be granted or that we will have the <font color="blue"><font color="blue">necessary</font> funds</font> to develop certain     of our products</td>
    </tr>
    <tr>
      <td>Any failure to obtain, or delay in obtaining <font color="blue">such approvals</font>     or <font color="blue">clearances</font>, could <font color="blue"><font color="blue">adversely</font> affect</font> our ability to market our products</td>
    </tr>
    <tr>
      <td><font color="blue">Substantial </font><font color="blue">competition</font> could <font color="blue">materially</font> affect our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>We  compete  with  many  companies,  including,  among  others,  large     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> and specialized <font color="blue">medical products</font> companies</td>
    </tr>
    <tr>
      <td>Many of     these companies have <font color="blue">substantially</font> greater financial and other resources,     larger  research  and <font color="blue">development</font> staffs, more extensive marketing and     <font color="blue">manufacturing</font> <font color="blue">organizations</font> and more experience in the <font color="blue">regulatory</font> process     than us</td>
    </tr>
    <tr>
      <td>We also compete with <font color="blue">academic institutions</font>, governmental agencies     and  other  research  <font color="blue">organizations</font>  that may be involved in research,     <font color="blue">development</font> and <font color="blue">commercialization</font> of products</td>
    </tr>
    <tr>
      <td>Because a number of companies     are developing or have developed HA products for similar <font color="blue">application</font>s and     have received FDA approval, the successful <font color="blue">commercialization</font> of a particular     <font color="blue">product will depend</font> in part upon our ability to complete <font color="blue">clinical studies</font>     and obtain FDA marketing and foreign <font color="blue"><font color="blue">regulatory</font> approval</font>s prior to our     <font color="blue">competitors</font>,  or,  if  <font color="blue">regulatory</font>  approval  is  not obtained prior to     <font color="blue">competitors</font>, to identify markets for our products that may be sufficient to     permit  <font color="blue">meaningful sales</font> of our products</td>
    </tr>
    <tr>
      <td>For example, we are aware of     <font color="blue">several companies</font> that are developing and/or marketing products utilizing HA     for a variety of human <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>In some cases, <font color="blue">competitors</font> have already     obtained product approvals, submitted <font color="blue">application</font>s for approval or have     commenced human <font color="blue">clinical studies</font>, either in the US or in <font color="blue">certain foreign</font>     countries</td>
    </tr>
    <tr>
      <td>There  exist <font color="blue">major competing products</font> for the use of HA in     ophthalmic surgery</td>
    </tr>
    <tr>
      <td>In addition, certain HA products for the treatment of     <font color="blue">osteoarthritis</font> in the knee have received FDA approval before us and have     <font color="blue">been marketed</font> in the US since 1997, as well as select markets in Canada,     Europe and other countries</td>
    </tr>
    <tr>
      <td>In early 2004 the FDA <font color="blue">approved two</font> HA products     for the treatment of <font color="blue">facial wrinkles which</font> has <font color="blue">been marketed</font> <font color="blue">international</font>ly     since  1996</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able to compete     <font color="blue">against current</font> or future <font color="blue">competitors</font> or that <font color="blue">competition</font> will not have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are uncertain regarding the success of our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Several of our products will require <font color="blue"><font color="blue">clinical trial</font>s</font> to determine their     safety  and  efficacy for US and <font color="blue">international</font> <font color="blue">marketing approval</font> by     <font color="blue">regulatory</font> bodies, including <font color="blue">the FDA We </font>completed a <font color="blue">pilot human clinical</font>     trial  in Europe for INCERT-S in <font color="blue">December </font>2005 and completed a pivotal     <font color="blue">clinical trial</font> for our product for <font color="blue">CTA in October </font>2005</td>
    </tr>
    <tr>
      <td>There can be no     assurance that we will be able to <font color="blue">successfully</font> complete the US <font color="blue">regulatory</font>     <font color="blue">approval process</font> for either INCERT-S or our CTA product</td>
    </tr>
    <tr>
      <td>In addition, there     can be no assurance that we will not encounter <font color="blue">additional</font> problems that will     cause us to delay, suspend or terminate the <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, we     cannot make any assurance that such <font color="blue"><font color="blue">clinical trial</font>s</font>, if completed, will     <font color="blue">ultimately demonstrate</font> these products to be safe and <font color="blue">efficacious</font></td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________       We are <font color="blue"><font color="blue">dependent</font> upon marketing</font> and <font color="blue">distribution</font> partners and the failure to     maintain  <font color="blue"><font color="blue">strategic alliances</font> on</font> acceptable terms will have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will</font> be <font color="blue">dependent</font>, in part, upon the efforts of our marketing     partners  and  the terms and <font color="blue">conditions</font> of our <font color="blue"><font color="blue">relationships</font> with such</font>     <font color="blue">marketing partners</font></td>
    </tr>
    <tr>
      <td>We  cannot  assure  you  that such <font color="blue">marketing partners</font> will not seek to     <font color="blue">renegotiate</font> their <font color="blue">current <font color="blue">agreement</font>s on terms less</font> favorable to us</td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font>the terms of the 2004 B&amp;L Agreement, <font color="blue">effective</font> <font color="blue">December </font>15, 2004, we will     continue to be Bausch &amp; Lomb’s <font color="blue">exclusive global supplier</font> (other than with     respect  to  Japan)  of AMVISC and AMVISC Plus <font color="blue">ophthalmic <font color="blue">viscoelastic</font></font>     products</td>
    </tr>
    <tr>
      <td>The B&amp;L Agreement expires <font color="blue">December </font>31, 2010, and superseded an     existing  supply  contract  with  Bausch &amp; Lomb that was set to expire     <font color="blue">December </font>31,  2007</td>
    </tr>
    <tr>
      <td>The <font color="blue">new contract also provides us with</font> a right to     negotiate to <font color="blue">manufacture</font> future surgical <font color="blue">ophthalmic <font color="blue">viscoelastic</font></font> products     developed by Bausch &amp; Lomb, while Bausch &amp; Lomb has <font color="blue">been granted rights</font> to     <font color="blue">commercialize</font> certain future surgical <font color="blue">ophthalmic <font color="blue">viscoelastic</font></font> products     developed by us</td>
    </tr>
    <tr>
      <td>In addition, under <font color="blue">certain <font color="blue">circumstances</font></font>, Bausch &amp; Lomb has     the right to terminate the <font color="blue">agreement</font>, and/or the <font color="blue"><font color="blue">agreement</font> may revert</font> to a     non-exclusive basis; in each case, we cannot make any assurances that such     <font color="blue"><font color="blue">circumstances</font> will</font> not occur</td>
    </tr>
    <tr>
      <td>For the years ended <font color="blue">December </font>31, 2005 and     2004, sales of AMVISC products to Bausch &amp; Lomb accounted for 31prca and 32prca of     <font color="blue">total revenue</font>s, respectively</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">distributor</font>  for  CoEase,  Advanced Medical Optics, completed its     <font color="blue">previously</font> announced <font color="blue">acquisition</font> of the <font color="blue">surgical ophthalmology</font> business of     Pfizer, Inc</td>
    </tr>
    <tr>
      <td>in June 2004, which includes a <font color="blue">competing line</font> of <font color="blue">viscoelastic</font>     products for use in <font color="blue">ocular surgery</font></td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">agreement</font> with Advanced     Medical  Optics  was  not renewed and terminated in June 2005 upon its     expiration</td>
    </tr>
    <tr>
      <td><font color="blue">Sales to Advanced Medical Optics </font>were less than 1prca of total     revenue for 2005 compared to 8prca of <font color="blue">total revenue</font> for 2004 or <font color="blue">approximately</font>     dlra2dtta2 million</td>
    </tr>
    <tr>
      <td>As a result, in the future we may not be able to sustain     <font color="blue">current <font color="blue">product revenue</font> levels</font> in our ophthalmic business</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> various <font color="blue">agreement</font>s for the <font color="blue">distribution</font> of ORTHOVISC     <font color="blue">international</font>ly   which  are  subject  to  <font color="blue">termination</font>  under  certain     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>We are continuing to seek to establish long-term <font color="blue">distribution</font>     <font color="blue">relationships</font> in regions not covered by existing <font color="blue">agreement</font>s, but can make no     assurances that we will be successful in doing so</td>
    </tr>
    <tr>
      <td>There can be no assurance     that we will be able to identify or engage appropriate <font color="blue">distribution</font> or     <font color="blue">collaboration partners</font> or <font color="blue">effective</font>ly transition to any <font color="blue">such partners</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can be no assurance that we will obtain European or other <font color="blue">reimbursement</font>     approvals or, if <font color="blue">such approvals</font> are obtained, they will be obtained on a     <font color="blue">timely basis</font> or at a satisfactory level of <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2003 we <font color="blue">entered into</font> a ten-year licensing and supply <font color="blue">agreement</font>     with Ortho Biotech Products, LP, a member of the Johnson &amp; Johnson family     of companies, to market ORTHOVISC in the US and Mexico</td>
    </tr>
    <tr>
      <td>This <font color="blue">agreement</font> was     assigned to DePuy Mitek, Inc</td>
    </tr>
    <tr>
      <td>Under this Agreement, DePuy Mitek     performs sales, marketing and <font color="blue">distribution</font> functions</td>
    </tr>
    <tr>
      <td>Additionally, DePuy     Mitek has the right under <font color="blue">certain <font color="blue">circumstances</font></font>, to further develop and     <font color="blue">commercialize</font> ORTHOVISC as well as other <font color="blue">new products</font> for the treatment of     pain  associated with <font color="blue">osteoarthritis</font> based on our <font color="blue">viscosupplementation</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">Depuy Mitek </font>will be able to market     ORTHOVISC <font color="blue">effective</font>ly or to <font color="blue">establish sales levels</font> to the extent that Anika     and <font color="blue">Depuy Mitek </font>believe are possible in the timeframes expected, or at all,     nor can we assure you that we will be able to achieve the performance- and     sales- based milestones provided in the JNJ Agreement</td>
    </tr>
    <tr>
      <td>For the year ended     <font color="blue">December </font>31, 2004, sales of ORTHOVISC to <font color="blue">Depuy Mitek </font>and royalties tied to     end-user sales accounted for 18prca of <font color="blue">total revenue</font></td>
    </tr>
    <tr>
      <td>Furthermore, we cannot     <font color="blue">predict whether</font> the <font color="blue">license granted</font> to <font color="blue">Depuy Mitek </font>in the JNJ Agreement to     further develop and <font color="blue">commercialize</font> ORTHOVISC products for the treatment of     pain  associated with <font color="blue">osteoarthritis</font> based on our <font color="blue">viscosupplementation</font>     <font color="blue">technology</font> will result in any <font color="blue">new products</font> or <font color="blue">indications</font> for use</td>
    </tr>
    <tr>
      <td>On  July 26,  2004, we announced the signing of an <font color="blue">exclusive worldwide</font>     <font color="blue">development</font>  and  <font color="blue">commercialization</font> partnership with <font color="blue">OrthoNeutrogena </font>a     division of Ortho-McNeil Pharmaceuticals, Inc, an affiliate of Johnson &amp;     Johnson, for our CTA <font color="blue">therapy products</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">September </font>1, 2005, the <font color="blue">Company       </font>14     ______________________________________________________________________       announced that it had <font color="blue">mutually agreed with</font> <font color="blue">OrthoNeutrogena </font>to terminate its     <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">agreement</font>, and that we were seeking a new     worldwide <font color="blue">distribution</font> partner</td>
    </tr>
    <tr>
      <td>Also on <font color="blue">September </font>1, 2005, we announced we     had filed our PMA with the FDA <font color="blue">seeking approval</font> to market and sell our CTA     product  in  the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will     <font color="blue">successfully</font>  complete  the  FDA  approval  process</td>
    </tr>
    <tr>
      <td>If we are able to     <font color="blue">successfully</font> complete the FDA <font color="blue">approval process</font> for our CTA product, we     <font color="blue">cannot assure</font> you that we will be able to <font color="blue">successfully</font> find a <font color="blue">distribution</font>     partner and <font color="blue">commercialize</font> our CTA product <font color="blue">effective</font>ly, or at all</td>
    </tr>
    <tr>
      <td>We may need to obtain the assistance of <font color="blue">additional</font> <font color="blue">marketing partners</font> to     <font color="blue">bring new</font> and <font color="blue">existing products</font> to market and to <font color="blue">replace certain marketing</font>     partners</td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">establish strategic partnerships</font> for the marketing     and <font color="blue">distribution</font> of our <font color="blue">products on</font> acceptable terms will have a material     adverse  effect  on  our business, <font color="blue">financial condition</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will</font> depend in part upon the <font color="blue">acceptance</font> of our existing and     <font color="blue"><font color="blue">future products</font> by</font> the <font color="blue">medical community</font>, hospitals and physicians and other     <font color="blue">health care providers</font>, and third-party payers</td>
    </tr>
    <tr>
      <td>Such <font color="blue">acceptance</font> may depend     upon the extent to which the <font color="blue">medical community</font> perceives our products as     safer, more <font color="blue">effective</font> or cost-<font color="blue">competitive</font> than other similar products</td>
    </tr>
    <tr>
      <td>Ultimately, for our <font color="blue">new products</font> to gain general market <font color="blue">acceptance</font>, it may     also be <font color="blue">necessary</font> for us to develop <font color="blue">marketing partners</font> for the <font color="blue">distribution</font>     of  our products</td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue">new products</font> will     achieve <font color="blue">significant</font> market <font color="blue">acceptance</font> on a <font color="blue">timely basis</font>, or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Failure     </font>of  some  or  all of our <font color="blue">future products</font> to achieve <font color="blue">significant</font> market     <font color="blue">acceptance</font> could have a material adverse effect on our business, financial     condition, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">adequately protect</font> our <font color="blue">intellectual property rights</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will</font> depend, in part, on our ability to obtain and enforce     patents, protect <font color="blue">trade secrets</font>, obtain licenses to <font color="blue">technology</font> owned by third     parties when <font color="blue">necessary</font>, and conduct our business <font color="blue">without infringing on</font> the     <font color="blue">proprietary</font>  rights of others</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font>,     <font color="blue">medical products</font> and bio<font color="blue">technology</font> firms, including ours, can be uncertain     and <font color="blue">involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>There can be no assurance     that any patent <font color="blue">application</font>s will result in the issuance of patents or, if     any patents are issued, whether they will provide <font color="blue">significant</font> <font color="blue">proprietary</font>     protection or <font color="blue">commercial advantage</font>, or will not be <font color="blue">circumvented by others</font></td>
    </tr>
    <tr>
      <td>In the event a third party has also filed one or more patent <font color="blue">application</font>s     for  any of its <font color="blue">inventions</font>, we may have to <font color="blue">participate</font> in <font color="blue">interference</font>     <font color="blue">proceedings</font> declared by the <font color="blue">United States</font> Patent and Trademark Office (PTO)     to determine priority of invention, which could result in failure to obtain,     or the loss of, <font color="blue">patent protection</font> for the <font color="blue">inventions</font> and the loss of any     right to use the <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Even if the <font color="blue">eventual outcome</font> is favorable to     us, such <font color="blue">interference</font> <font color="blue">proceedings</font> could result in substantial cost to us,     and diversion of <font color="blue">management</font>’s attention away from our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Filing and     <font color="blue">prosecution</font> of patent <font color="blue">application</font>s, <font color="blue">litigation</font> to establish the validity and     scope of patents, assertion of patent <font color="blue">infringement</font> claims against others and     the defense of patent <font color="blue">infringement</font> claims by others can be expensive and     time consuming</td>
    </tr>
    <tr>
      <td>There can be no assurance that in the event that any claims     <font color="blue">with respect</font> to any of our patents, if issued, are <font color="blue">challenged by one</font> or more     <font color="blue">third parties</font>, that any court or <font color="blue">patent authority ruling on such challenge</font>     will determine that <font color="blue">such patent</font> claims are valid and enforceable</td>
    </tr>
    <tr>
      <td>An adverse     outcome in such <font color="blue">litigation</font> could cause us to <font color="blue">lose exclusivity covered by</font> the     <font color="blue">disputed rights</font></td>
    </tr>
    <tr>
      <td>If a third party is found to have rights covering products     or processes used by us, we could be forced to cease using the <font color="blue">technologies</font>     or  marketing the products covered by such rights, could be subject to     <font color="blue">significant</font>  <font color="blue">liabilities</font> to such third party, and could be required to     license <font color="blue">technologies</font> from such third party</td>
    </tr>
    <tr>
      <td>Furthermore, even if our patents     are determined to be valid, enforceable, and broad in scope, there can be no     assurance that <font color="blue">competitors</font> will not be able to <font color="blue">design around</font> <font color="blue">such patent</font>s     and <font color="blue">compete with us using</font> the resulting alternative <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________       We have a policy of seeking <font color="blue">patent protection</font> for <font color="blue">patentable aspects</font> of our     <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We intend to seek <font color="blue">patent protection</font> <font color="blue">with respect</font> to     products and processes developed in the course of our <font color="blue">activities</font> when we     believe <font color="blue">such protection</font> is in our <font color="blue">best interest</font> and when the cost of seeking     <font color="blue">such protection</font> is not inordinate</td>
    </tr>
    <tr>
      <td>However, no assurance can be given that     any patent <font color="blue">application</font> will be filed, that any filed <font color="blue">application</font>s will     result in issued patents or that any issued patents will provide us with a     <font color="blue">competitive</font>  advantage or will not be <font color="blue">successfully</font> challenged by third     parties</td>
    </tr>
    <tr>
      <td>The <font color="blue">protections afforded by patents will <font color="blue">depend upon</font></font> their scope     and validity, and <font color="blue">others may</font> be able to <font color="blue">design around</font> our patents</td>
    </tr>
    <tr>
      <td>Other  entities have filed patent <font color="blue">application</font>s for or have <font color="blue">been issued</font>     <font color="blue">patents concerning various aspects</font> of HA-related products or processes</td>
    </tr>
    <tr>
      <td>There can be no assurance that the products or processes developed by us     will not infringe on the <font color="blue">patent rights</font> of others in the future</td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">infringement</font> may have a material adverse effect on our business, financial     condition, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In particular, we received notice from     the  PTO in 1995 that a third party was attempting to provoke a patent     <font color="blue">interference</font> <font color="blue">with respect</font> to one of our co-owned patents covering the use of     INCERT for post-surgical adhesion prevention</td>
    </tr>
    <tr>
      <td>It is <font color="blue">unclear whether</font> an     <font color="blue">interference</font> will be declared</td>
    </tr>
    <tr>
      <td>If an <font color="blue">interference</font> is declared it is not     possible at this time to determine the merits of the <font color="blue">interference</font> or the     effect, if any, the <font color="blue">interference</font> will have on our marketing of INCERT for     this use</td>
    </tr>
    <tr>
      <td>No assurance can be given that we would be successful in any such     <font color="blue">interference</font> proceeding</td>
    </tr>
    <tr>
      <td>If the third-party <font color="blue">interference</font> were to be decided     <font color="blue">adversely</font> to us, involved claims of our patent would be cancelled, our     marketing <font color="blue">of the INCERT </font><font color="blue">product may</font> be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font>ed and     the third party may enforce <font color="blue">patent rights</font> <font color="blue">against us</font> which could prohibit     the sale and use of INCERT products, which could have a material adverse     effect on our future operating results</td>
    </tr>
    <tr>
      <td>We  also  <font color="blue">rely upon <font color="blue">trade secrets</font></font> and <font color="blue">proprietary</font> know-how for certain     non-patented aspects of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">protect such</font> information, we     require  all  employees,  <font color="blue">consultants</font>  and  licensees  to  enter  into     <font color="blue">confidentiality</font>  <font color="blue">agreement</font>s  limiting  the  <font color="blue">disclosure</font> and use of such     information</td>
    </tr>
    <tr>
      <td>There  can be no assurance that these <font color="blue">agreement</font>s provide     <font color="blue">meaningful protection</font> or that they will not be breached, that we would have     adequate  remedies  for  any  such  breach, or that our <font color="blue">trade secrets</font>,     <font color="blue">proprietary</font> know-how, and our <font color="blue"><font color="blue">technological</font> advances will</font> not otherwise     <font color="blue">become known</font> to others</td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance that, despite     precautions taken by us, others have not and will not obtain access to our     <font color="blue">proprietary</font>  <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Further, there can be no assurance that third     <font color="blue">parties will</font> not in<font color="blue">dependent</font>ly develop <font color="blue">substantially</font> equivalent or better     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Pursuant to the 2004 B&amp;L Agreement, we have agreed to transfer to Bausch &amp;     Lomb, <font color="blue">upon expiration</font> of the term of the 2004 B&amp;L <font color="blue">agreement</font> on <font color="blue">December </font>31,     2010, or in connection with earlier <font color="blue">termination</font> in <font color="blue">certain <font color="blue">circumstances</font></font>,     our <font color="blue">manufacturing</font> process, know-how and technical information, which relate     to only AMVISC products</td>
    </tr>
    <tr>
      <td>Upon expiration of the 2004 B&amp;L Agreement, there     can  be  no  assurance  that  Bausch &amp; Lomb <font color="blue">will continue</font> to use us to     <font color="blue">manufacture</font> AMVISC and AMVISC Plus</td>
    </tr>
    <tr>
      <td>If Bausch &amp; Lomb <font color="blue">discontinues</font> the use of     us as a <font color="blue">manufacture</font>r after such time, our business, <font color="blue">financial condition</font>, and     results of <font color="blue">operations</font> would likely be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> processes involve <font color="blue">inherent risk</font>s and <font color="blue">disruption could</font>     <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font> our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> are <font color="blue">dependent</font> upon the <font color="blue">continued operation</font> of our     <font color="blue">manufacturing</font> facility in Woburn, Massachusetts</td>
    </tr>
    <tr>
      <td>The operation of biomedical     <font color="blue">manufacturing</font> plants involves many risks, including the risks of <font color="blue">breakdown</font>,     failure or <font color="blue">substandard performance</font> of equipment, the occurrence of natural     and  other  <font color="blue">disasters</font>, and the need to <font color="blue">comply with</font> the <font color="blue">requirements</font> of     <font color="blue">directives</font> of <font color="blue">government agencies</font>, including the FDA In addition, we rely     on a <font color="blue">single supplier</font> for syringes and a small number of suppliers for a     number of other materials required for the <font color="blue">manufacturing</font> and delivery of our     HA products</td>
    </tr>
    <tr>
      <td>Although we believe that <font color="blue">alternative sources</font> for many of these     and other <font color="blue">components</font> and <font color="blue">raw materials</font> that we use in our <font color="blue">manufacturing</font>     processes are available, any supply <font color="blue">interruption</font> could harm our ability to       16     ______________________________________________________________________       <font color="blue">manufacture</font> our <font color="blue">products until</font> a new source of supply is identified and     qualified</td>
    </tr>
    <tr>
      <td>We may not be able to find a <font color="blue">sufficient alternative supplier</font> in a     reasonable time period, or <font color="blue">on commercially reasonable terms</font>, if at all, and     our ability to produce and supply our <font color="blue">products could</font> be impaired</td>
    </tr>
    <tr>
      <td>Furthermore,  our <font color="blue">manufacturing</font> processes and research and <font color="blue">development</font>     <font color="blue">efforts involve animals</font> and <font color="blue">products <font color="blue">derived from</font> animals</font></td>
    </tr>
    <tr>
      <td>We procure our     animal-derived  raw  materials  from  qualified  vendors,  control for     <font color="blue">contamination</font> and have processes that <font color="blue">effective</font>ly inactivate infectious     agents; however, we <font color="blue">cannot assure</font> you that we can <font color="blue">completely eliminate</font> the     risk of <font color="blue">transmission</font> of <font color="blue">infectious agents</font> and in the future <font color="blue">regulatory</font>     <font color="blue">authorities</font> could impose restrictions on the use of animal-derived raw     materials that <font color="blue">could impact</font> our business</td>
    </tr>
    <tr>
      <td>The  <font color="blue">utilization</font>  of  animals  in research and <font color="blue">development</font> and product     <font color="blue">commercialization</font> is subject to <font color="blue">increasing focus by animal rights activists</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">activities</font> of animal rights groups and other <font color="blue">organizations</font> that have     <font color="blue">protested animal based research</font> and <font color="blue">development</font> programs or boycotted the     products resulting <font color="blue">from such programs could</font> cause an <font color="blue">interruption</font> in our     <font color="blue">manufacturing</font> processes and research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>The occurrence     of material <font color="blue">operational problems</font>, including but not limited to the events     described above, could have a material adverse effect on our business,     <font color="blue">financial condition</font>, and results of <font color="blue">operations</font> during the period of such     <font color="blue">operational <font color="blue"><font color="blue">difficult</font>ies</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial performance</font> depends on the <font color="blue">continued growth</font> and demand for our     products and we may not be able to <font color="blue">successfully</font> manage the expansion of our     <font color="blue">operations</font>       Our <font color="blue">future success depends on</font> substantial growth in <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>There can     be no assurance that <font color="blue">such growth</font> can be achieved or, if achieved, can be     sustained</td>
    </tr>
    <tr>
      <td>There can be no assurance that even if substantial growth in     <font color="blue">product sales</font> and the demand for our products is achieved, we will be able     to:       ·       develop the <font color="blue">necessary</font> <font color="blue">manufacturing</font> <font color="blue">capabilities</font>;       ·       obtain the assistance of <font color="blue">additional</font> <font color="blue">marketing partners</font>;       ·       attract, retain and integrate the required <font color="blue">key personnel</font>;       ·       implement the financial, <font color="blue">accounting</font> and <font color="blue"><font color="blue">management</font> systems</font> needed to     <font color="blue">manage growing demand</font> for our products</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">successfully</font> manage future growth could have a material     adverse  effect  on  our business, <font color="blue">financial condition</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we engage in any <font color="blue">acquisition</font> as a part our <font color="blue">growth strategy</font>, we will incur     a variety of costs, and may never realize the anticipated benefits of the     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">strategy may</font> include the future <font color="blue">acquisition</font> of <font color="blue">businesses</font>,     <font color="blue">technologies</font>, services or products that we believe are a <font color="blue">strategic fit with</font>     our business</td>
    </tr>
    <tr>
      <td>If we undertake any <font color="blue">acquisition</font>, the process of integrating an     acquired business, <font color="blue">technology</font>, service or <font color="blue">product may</font> result in unforeseen     operating  <font color="blue"><font color="blue">difficult</font>ies</font>  and  <font color="blue">expenditure</font>s  and may absorb <font color="blue">significant</font>     <font color="blue">management</font>  attention  that  would  otherwise be available for ongoing     <font color="blue">development</font>  of  our  business</td>
    </tr>
    <tr>
      <td>Moreover,  we may fail to realize the     anticipated benefits of any <font color="blue">acquisition</font> as rapidly as expected or at all</td>
    </tr>
    <tr>
      <td>Future <font color="blue">acquisition</font>s could reduce <font color="blue">stockholders</font>’ ownership, cause us to incur     debt, expose us to future <font color="blue">liabilities</font> and result in <font color="blue">amortization expenses</font>     related to <font color="blue">intangible assets with definite lives</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">acquisition</font>s     involve other risks, including diversion of <font color="blue">management</font> resources otherwise     available for ongoing <font color="blue">development</font> of our business and <font color="blue">risks associated with</font>     entering  new  markets  with which we have limited experience or where     experienced  <font color="blue">distribution</font>  alliances  are  not  available</td>
    </tr>
    <tr>
      <td>Our future     <font color="blue">profitability may depend</font> in part upon our ability to develop further our     resources to adapt to these <font color="blue">new products</font> or business areas and to identify     and <font color="blue">enter into</font> satisfactory       17     ______________________________________________________________________       <font color="blue">distribution</font> networks</td>
    </tr>
    <tr>
      <td>We may not be able to identify suitable <font color="blue">acquisition</font>     <font color="blue">candidates</font> in the future or consummate future <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>Sales of our products are largely <font color="blue">dependent</font> upon third party <font color="blue">reimbursement</font>     and  our  performance  may  be  harmed by health care cost <font color="blue">containment</font>     <font color="blue">initiatives</font></td>
    </tr>
    <tr>
      <td><font color="blue">In the US </font>and other markets, <font color="blue">health care providers</font>, such as hospitals and     physicians,  that purchase <font color="blue">health care product</font>s, such as our products,     <font color="blue">generally rely on <font color="blue">third party payers</font></font>, including Medicare, Medicaid and other     <font color="blue">health insurance</font> and <font color="blue">managed care</font> plans, to reimburse all or part of the     cost of the <font color="blue">health care product</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend upon</font> the <font color="blue">distributor</font>s for our     products to secure <font color="blue">reimbursement</font> and <font color="blue">reimbursement</font> approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement     </font><font color="blue">by <font color="blue">third party payers</font> may depend on</font> a number of factors, including the     payer’s de<font color="blue">termination</font> that the use of our products is <font color="blue">clinically useful</font> and     cost-<font color="blue">effective</font>, medically <font color="blue">necessary</font> and not <font color="blue">experimental</font> or <font color="blue">investigational</font></td>
    </tr>
    <tr>
      <td>Since <font color="blue">reimbursement</font> approval is required <font color="blue">from each payer individually</font>,     seeking <font color="blue">such approvals</font> can be a time consuming and <font color="blue">costly process which</font>, in     the future, could require us or our <font color="blue">marketing partners</font> to <font color="blue">provide supporting</font>     scientific, clinical and cost-<font color="blue"><font color="blue">effective</font>ness</font> data for the use of our products     to  each  payer  <font color="blue">separately</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the     <font color="blue">reimbursement</font> status of newly approved <font color="blue">health care product</font>s, and any failure     or delay in obtaining <font color="blue">reimbursement</font> approvals can <font color="blue">negatively impact sales</font> or     our  new  products</td>
    </tr>
    <tr>
      <td>In  addition, <font color="blue">third party payers</font> are increasingly     attempting to contain the costs of <font color="blue">health care product</font>s and <font color="blue">services by</font>     <font color="blue">limiting both coverage</font> and the level of <font color="blue">reimbursement</font> for <font color="blue">new therapeutic</font>     products and by refusing in some cases to <font color="blue">provide coverage</font> for uses of     <font color="blue">approved products</font> for disease <font color="blue">indications</font> for which the FDA has not granted     <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>Also, Congress and certain state <font color="blue">legislatures</font> have     considered  reforms  that  may affect current <font color="blue">reimbursement</font> practices,     including controls on health care spending through <font color="blue"><font color="blue">limitations</font> on</font> the growth     <font color="blue">of Medicare and Medicaid </font>spending</td>
    </tr>
    <tr>
      <td>There can be no assurance that third     party <font color="blue">reimbursement</font> coverage will be available or adequate for any products     or services developed by us</td>
    </tr>
    <tr>
      <td>Outside the US, the success of our products     is also <font color="blue">dependent</font> in part upon the <font color="blue">availability</font> of <font color="blue">reimbursement</font> and health     care payment systems</td>
    </tr>
    <tr>
      <td>Lack of <font color="blue">adequate coverage</font> and <font color="blue">reimbursement</font> provided     by <font color="blue">governments</font> and other <font color="blue">third party payers</font> for our products and services,     including continued classification by CMS of ORTHOVISC under a <font color="blue">miscellaneous</font>     J-code for Medicare/Medicaid <font color="blue">reimbursement</font>, could have a material adverse     effect on our business, <font color="blue">financial condition</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may seek financing</font> in the future, which could be <font color="blue">difficult</font> to obtain and     <font color="blue">which could dilute</font> your <font color="blue">ownership interest</font> or the value of your shares</td>
    </tr>
    <tr>
      <td>We  had  cash  and  <font color="blue">cash equivalents</font> of <font color="blue">approximately</font> dlra44dtta7 million at     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our future capital <font color="blue">requirements</font> and the adequacy of     available funds will depend, however, on numerous factors, including:       ·       market <font color="blue">acceptance</font> of our existing and <font color="blue">future products</font>;       ·       the success and sales of ORTHOVISC under the JNJ Agreement;       ·       the successful <font color="blue">commercialization</font> of products in <font color="blue">development</font>;       ·       progress in our product <font color="blue">development</font> efforts;       ·       the magnitude and scope of such product <font color="blue">development</font> efforts;       ·       progress with pre<font color="blue">clinical studies</font>, <font color="blue"><font color="blue">clinical trial</font>s</font> and product     <font color="blue">clearances</font> by the FDA and other agencies;       ·       the cost and timing of our efforts to manage our <font color="blue">manufacturing</font>     <font color="blue">capabilities</font> and related costs;       ·       the cost of filing, prosecuting, defending and <font color="blue">enforcing patent</font>     claims and other <font color="blue">intellectual property rights</font>;       18     ______________________________________________________________________       ·       <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s;       ·       the <font color="blue">development</font> of <font color="blue">strategic alliances</font> for the marketing of certain     of our products;       ·       the terms of such <font color="blue">strategic alliances</font>, including provisions (and our     ability to <font color="blue">satisfy such provisions</font>) that provide upfront and/or milestone     payments to us; and       ·       the cost of maintaining <font color="blue">adequate inventory levels</font> to <font color="blue">meet current</font>     and <font color="blue">future product demands</font></td>
    </tr>
    <tr>
      <td>To the extent that funds generated from our <font color="blue">operations</font>, together with our     existing capital resources are insufficient to meet future <font color="blue">requirements</font>, we     will  be  required  to  obtain <font color="blue">additional</font> funds through equity or debt     <font color="blue">financings</font>, <font color="blue">strategic alliances</font> with corporate partners and others, or     through other sources</td>
    </tr>
    <tr>
      <td>The terms of any future equity <font color="blue">financings</font> may be     dilutive to you and the terms of any debt <font color="blue">financings</font> may contain restrictive     covenants, which limit our ability to <font color="blue">pursue certain courses</font> of action</td>
    </tr>
    <tr>
      <td>Our     ability  to  obtain financing is <font color="blue">dependent</font> on the status of our future     business prospects as well as <font color="blue">conditions</font> prevailing in the <font color="blue">relevant capital</font>     markets</td>
    </tr>
    <tr>
      <td>No assurance can be given that any <font color="blue">additional</font> financing will be     made available to us or will be <font color="blue">available on</font> acceptable <font color="blue">terms should such</font> a     need arise</td>
    </tr>
    <tr>
      <td>We <font color="blue">could become</font> subject to <font color="blue">product liability</font> claims, which, if successful,     could <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font> our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The testing, marketing and sale of human <font color="blue">health care product</font>s entail an     <font color="blue">inherent risk</font> of <font color="blue">allegations</font> of <font color="blue">product liability</font>, and there can be no     assurance that substantial <font color="blue">product liability</font> claims will not be asserted     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Although we have not received any material <font color="blue">product liability</font>     claims to date and have an insurance policy of dlra5cmam000cmam000 per occurrence and     dlra5cmam000cmam000 in the aggregate to cover such claims should they arise, there     can be no assurance that material claims will not arise in the future or     that our <font color="blue">insurance will</font> be adequate to cover all situations</td>
    </tr>
    <tr>
      <td>Moreover, there     can  be  no assurance that <font color="blue">such insurance</font>, or <font color="blue">additional</font> insurance, if     required,  will  be  available in the future or, if available, will be     available <font color="blue">on commercially reasonable terms</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">product liability</font> claim, if     successful, could have a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">dependent</font> upon hiring and retaining qualified <font color="blue">management</font> and     <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent</font> on the members of our <font color="blue">management</font> and scientific     staff, the loss of one or more of whom could have a material adverse effect     on us</td>
    </tr>
    <tr>
      <td>We experienced a number of <font color="blue">management</font> changes in 2004 and 2005</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can be <font color="blue">no assurances</font> that such <font color="blue">management</font> changes will not <font color="blue"><font color="blue">adversely</font> affect</font>     our business</td>
    </tr>
    <tr>
      <td>We believe that our future <font color="blue">success will</font> depend in large part     upon  our  ability  to  attract and retain highly skilled, scientific,     managerial and <font color="blue">manufacturing</font> personnel</td>
    </tr>
    <tr>
      <td>We face <font color="blue">significant</font> <font color="blue">competition</font> for     <font color="blue">such personnel from</font> other companies, research and <font color="blue">academic institutions</font>,     <font color="blue">government entities</font> and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>The     failure to hire and retain <font color="blue">such personnel could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">environmental regulation</font> and any failure to <font color="blue">comply with</font>     <font color="blue">applicable laws could</font> subject us to <font color="blue">significant</font> <font color="blue">liabilities</font> and harm our     business</td>
    </tr>
    <tr>
      <td>We  are  subject  to  a variety of local, state and <font color="blue">federal government</font>     <font color="blue">regulations</font>  relating  to  the storage, discharge, handling, emission,     generation, <font color="blue">manufacture</font> and disposal of toxic, or other <font color="blue">hazardous substances</font>     used in the <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure by us</font> to control the     use, disposal, removal or storage of <font color="blue">hazardous chemicals</font> or <font color="blue">toxic substances</font>     could subject us to <font color="blue">significant</font> <font color="blue">liabilities</font>, which could have a material     adverse  effect  on  our business, <font color="blue">financial condition</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       Our future operating results may be harmed by economic, political and other     risks relating to <font color="blue">international</font> sales</td>
    </tr>
    <tr>
      <td>During the years ended <font color="blue">December </font>31, 2005 and 2004, <font color="blue">approximately</font>, 43prca and     30prca, respectively, of our <font color="blue">product sales</font> were to <font color="blue">international</font> <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">representatives</font>,  agents  and  <font color="blue">distributor</font>s  who <font color="blue">sell products</font> in     <font color="blue">international</font> markets are subject to the laws and <font color="blue">regulations</font> of the foreign     <font color="blue">jurisdictions</font> in which they operate and in which our products are sold</td>
    </tr>
    <tr>
      <td>A     number of risks are inherent in <font color="blue">international</font> sales and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For     example, the volume of <font color="blue">international</font> sales may be limited by the imposition     of  government controls, export license <font color="blue">requirements</font>, political and/or     economic instability, trade restrictions, changes in tariffs, <font color="blue"><font color="blue">difficult</font>ies</font>     in managing <font color="blue">international</font> <font color="blue">operations</font>, import restrictions and <font color="blue">fluctuations</font>     in <font color="blue">foreign currency exchange rates</font></td>
    </tr>
    <tr>
      <td>Such changes in the volume of sales may     have a material adverse effect on our business, <font color="blue">financial condition</font>, and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our stock price has been and <font color="blue">may remain <font color="blue">highly volatile</font></font>, and we cannot     assure you that market making in our <font color="blue">common stock</font> <font color="blue">will continue</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of shares of our <font color="blue"><font color="blue">common stock</font> may</font> be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Factors <font color="blue">such as announcements</font> of <font color="blue">new commercial products</font> or <font color="blue">technological</font>     innovations by us or our <font color="blue">competitors</font>, <font color="blue">disclosure</font> of results of clinical     testing or <font color="blue">regulatory</font> <font color="blue">proceedings</font>, governmental regulation and approvals,     <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font> rights, public concern as to the     safety of products developed by us and general market <font color="blue">conditions</font> may have a     <font color="blue">significant</font> effect on the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The trading     price of our <font color="blue">common stock</font> could be subject to wide <font color="blue">fluctuations</font> in response     to  quarter-to-quarter  <font color="blue">variations</font>  in our operating results, material     <font color="blue">announcements by us</font> or our <font color="blue">competitors</font>, governmental <font color="blue">regulatory</font> action,     <font color="blue">conditions</font> in the <font color="blue">health care industry generally</font> or in the <font color="blue">medical products</font>     <font color="blue">industry specifically</font>, or other events or factors, many of which are beyond     our control</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> has experienced <font color="blue">extreme price</font> and     volume <font color="blue">fluctuations</font> which have <font color="blue">particularly affected</font> the <font color="blue">market price</font>s of     many <font color="blue">medical products</font> companies and <font color="blue">which often</font> have <font color="blue">been unrelated</font> to the     operating performance of <font color="blue">such companies</font></td>
    </tr>
    <tr>
      <td>Our operating results in future     <font color="blue">quarters may</font> be below the <font color="blue">expectations</font> of <font color="blue">equity research analysts</font> and     investors</td>
    </tr>
    <tr>
      <td>In  such event, the price of our <font color="blue">common stock</font> would likely     decline, perhaps <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>No person is under any <font color="blue">obligation</font> to make a market in the <font color="blue">common stock</font> or to     <font color="blue">publish research</font> reports on us, and any person making a market in the common     stock or publishing research reports <font color="blue">on us may discontinue market</font> making or     publishing  such  reports  at any time without notice</td>
    </tr>
    <tr>
      <td>There can be no     assurance  that  an  active  <font color="blue">public market</font> in our <font color="blue">common stock</font> will be     sustained</td>
    </tr>
    <tr>
      <td>Our charter <font color="blue">documents</font> contain anti-takeover provisions that <font color="blue">may prevent</font> or     delay an <font color="blue">acquisition</font> of us</td>
    </tr>
    <tr>
      <td>Certain provisions of our <font color="blue">Restated Articles of Organization and Amended </font>and     Restated By-laws could have the effect of <font color="blue">discouraging</font> a <font color="blue">third party from</font>     pursuing a non-negotiated takeover of us and <font color="blue">preventing certain</font> changes in     control</td>
    </tr>
    <tr>
      <td>These provisions include a classified <font color="blue">Board of Directors</font>, advance     notice to the <font color="blue">Board of <font color="blue">Directors </font></font>of stockholder proposals, <font color="blue"><font color="blue">limitations</font> on</font>     the ability of <font color="blue">stockholders</font> to remove <font color="blue">directors</font> and to <font color="blue">call stockholder</font>     meetings, the provision that <font color="blue">vacancies on</font> the <font color="blue">Board of <font color="blue">Directors </font></font>be filled     by vote of a majority of the remaining <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>In addition, the Board of     <font color="blue">Directors </font>adopted a <font color="blue">Shareholders Rights Plan in April </font>1998</td>
    </tr>
    <tr>
      <td>We are also     subject to Chapter 110F of the <font color="blue">Massachusetts </font>General Laws which, subject to     certain exceptions, prohibits a <font color="blue">Massachusetts </font><font color="blue">corporation from</font> engaging in     any  of  a  broad  range of business <font color="blue">combinations with</font> any “interested     stockholder”  for a period of <font color="blue">three years following</font> the date that such     stockholder  became  an <font color="blue">interested stockholder</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font>     discourage  a  third  party  <font color="blue">from pursuing</font> a takeover of us at a price     considered <font color="blue">attractive by</font> many <font color="blue">stockholders</font>, since such <font color="blue">provisions could</font> have     the effect of preventing or delaying a <font color="blue">potential acquirer from</font> acquiring     control of us and our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       Our revenues are <font color="blue">derived from</font> a small number of customers, the loss of which     could <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font> our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">historically</font> derived</font> the majority of our <font color="blue">revenues from</font> a small     number of customers, most of whom resell our products to end users and most     of whom are <font color="blue">significant</font>ly larger companies than us</td>
    </tr>
    <tr>
      <td>For the year ended     <font color="blue">December </font>31, 2005, three customers accounted for 78prca of <font color="blue">product revenue</font></td>
    </tr>
    <tr>
      <td>While it is expected that our ability to market ORTHOVISC in the US will     reduce our dependence on <font color="blue">revenues from</font> Bausch &amp; Lomb, <font color="blue">historically</font> our     largest customer, we will still be <font color="blue">dependent</font> on a small number of large     customers for the majority of our revenues</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">generate as</font> much     <font color="blue">revenue as</font> expected from these customers or the failure of these customers     to purchase our <font color="blue">products would seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>In addition, if     present and <font color="blue">future customers terminate</font> their <font color="blue">purchasing arrangements with</font>     us, <font color="blue">significant</font>ly reduce or delay their orders, or seek to <font color="blue">renegotiate</font> their     <font color="blue">agreement</font>s on terms less favorable to us, our business, <font color="blue">financial condition</font>,     and results of <font color="blue">operations</font> will be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>If we <font color="blue">accept terms</font>     less favorable than the terms of the current <font color="blue">agreement</font>, such renegotiations     may have a material adverse effect on our business, <font color="blue">financial condition</font>,     and/or  results  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may be subject to the     perceived or <font color="blue">actual leverage</font> the <font color="blue">customers may</font> have given their relative     size and importance to us in any <font color="blue">future negotiations</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">termination</font>,     change, reduction or delay in <font color="blue">orders could seriously harm</font> our business,     <font color="blue">financial condition</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Accordingly, unless and     until we diversify and expand our <font color="blue">customer base</font>, our future <font color="blue">success will</font>     <font color="blue">significant</font>ly <font color="blue">depend upon</font> the timing and size of <font color="blue">future purchases by</font> our     largest  customers  and the financial and <font color="blue">operational success</font> of these     customers</td>
    </tr>
    <tr>
      <td>The loss of any one of our <font color="blue">major customers</font> or the delay of     <font color="blue">significant</font> orders from such customers, even if only temporary, could reduce     or delay our <font color="blue">recognition</font> of revenues, harm our reputation in the industry,     and  reduce  our  ability  to  <font color="blue">accurately predict cash flow</font>, and, as a     consequence, could seriously harm our business, <font color="blue">financial condition</font>, and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>costs for <font color="blue">complying with recent</font> and <font color="blue">proposed future</font> changes in     Securities and Exchange Commission, Nasdaq Stock Market and <font color="blue">accounting</font>     rules could <font color="blue"><font color="blue">adversely</font> affect</font> our profits</td>
    </tr>
    <tr>
      <td>Recent and future changes in the Securities and Exchange Commission and     Nasdaq rules, as well as changes in <font color="blue">accounting</font> rules, will cause us to incur     <font color="blue">additional</font>  costs  including  professional fees, as well as <font color="blue">additional</font>     <font color="blue">personnel costs</font>, in order to keep informed of the changes and operate in a     <font color="blue">compliant manner</font></td>
    </tr>
    <tr>
      <td>In addition, we have and continue to expect to incur     general  and  <font color="blue">administrative</font>  expense  as  we maintain <font color="blue">compliance with</font>     Section 404 of the Sarbanes-Oxley Act of 2002, which requires <font color="blue">management</font> to     report on, and our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm to attest     to, our internal controls</td>
    </tr>
    <tr>
      <td>These costs may be <font color="blue">significant</font> enough to cause     our <font color="blue">financial position</font> and results of <font color="blue">operations</font> to be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">compliance with</font> these new rules <font color="blue">could also</font> result in continued     diversion  of <font color="blue">management</font>’s time and attention, which could prove to be     <font color="blue">disruptive</font> to our normal business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> any of     the new laws and <font color="blue">regulations</font> could <font color="blue">adversely</font> impact market perception of our     company, which could make it <font color="blue">difficult</font> to access the <font color="blue">capital markets</font> or     <font color="blue">otherwise finance</font> our <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>With  new rules, including the Sarbanes-Oxley Act of 2002, we may have     <font color="blue">difficult</font>y in retaining or attracting <font color="blue">directors</font> for the board and various     sub-committees thereof or officers</td>
    </tr>
    <tr>
      <td>The recent changes in <font color="blue">SEC and Nasdaq </font>rules, including those resulting from     the Sarbanes-Oxley Act of 2002, may result in our being unable to attract     and retain the <font color="blue">necessary</font> board <font color="blue">directors</font> and members of sub-committees     thereof  or  officers,  to <font color="blue">effective</font>ly provide for our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>The     perceived increased personal risk associated with these recent changes may     <font color="blue">deter qualified individuals from</font> wanting to <font color="blue">participate</font> in these roles</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       We may have <font color="blue">difficult</font>y obtaining adequate <font color="blue">directors</font> and <font color="blue">officers insurance</font>     and the cost for coverage may <font color="blue">significant</font>ly increase</td>
    </tr>
    <tr>
      <td>We  may have <font color="blue">difficult</font>y in obtaining adequate <font color="blue">directors</font>’ and officers’     insurance to <font color="blue">protect us</font> and our <font color="blue">directors</font> and <font color="blue">officers from</font> claims made     <font color="blue">against them</font></td>
    </tr>
    <tr>
      <td>Additionally, even if <font color="blue">adequate coverage</font> is available, the     costs for <font color="blue">such coverage may</font> be <font color="blue">significant</font>ly greater than current costs</td>
    </tr>
    <tr>
      <td>This <font color="blue">additional</font> cost may have a <font color="blue">significant</font> effect on our profits and as a     consequence our results of <font color="blue">operations</font> may be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
  </tbody>
</table>